Detalles de la búsqueda
1.
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Ann Oncol
; 30(8): 1381-1392, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31114846
2.
The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients.
Ann Oncol
; 29(7): 1588-1593, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29722789
3.
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Ann Oncol
; 29(8): 1807-1813, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29992241
4.
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine.
Ann Oncol
; 28(1): 169-174, 2017 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28177438
5.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
Ann Oncol
; 28(3): 590-596, 2017 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27993804
6.
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
Ann Oncol
; 28(11): 2827-2835, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28950289
7.
How to report toxicity associated with targeted therapies?
Ann Oncol
; 27(8): 1633-8, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27217543
8.
Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer.
Breast Cancer Res Treat
; 156(3): 577-585, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27075918
9.
Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.
Clin Exp Dermatol
; 41(1): 34-7, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25959005
10.
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
Br J Cancer
; 112(4): 650-9, 2015 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25625276
11.
Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study.
Ann Oncol
; 26(3): 598-607, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25488684
12.
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
Ann Oncol
; 26(5): 1005-1011, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25646368
13.
Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.
BMC Cancer
; 15: 700, 2015 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26472661
14.
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.
Br J Cancer
; 111(1): 17-24, 2014 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24762958
15.
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Ann Oncol
; 25(3): 682-688, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24567516
16.
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
Invest New Drugs
; 31(3): 724-33, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22996801
17.
[Adverse skin reactions induced by BRAF inhibitors: a systematic review]. / Effets indésirables cutanés des inhibiteurs de BRAF: revue systématique.
Ann Dermatol Venereol
; 140(8-9): 510-20, 2013.
Artículo
en Francés
| MEDLINE | ID: mdl-24034635
18.
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.
ESMO Open
; 8(4): 101610, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37536254
19.
[Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology]. / Toxicité dermatologique des nouvelles thérapies ciblées anticancéreuses utilisées en oncodermatologie.
Ann Chir Plast Esthet
; 57(2): 106-13, 2012 Apr.
Artículo
en Francés
| MEDLINE | ID: mdl-22425393
20.
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.
ESMO Open
; 7(3): 100468, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35533427